BRPI0712158B8 - processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada - Google Patents

processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada

Info

Publication number
BRPI0712158B8
BRPI0712158B8 BRPI0712158A BRPI0712158A BRPI0712158B8 BR PI0712158 B8 BRPI0712158 B8 BR PI0712158B8 BR PI0712158 A BRPI0712158 A BR PI0712158A BR PI0712158 A BRPI0712158 A BR PI0712158A BR PI0712158 B8 BRPI0712158 B8 BR PI0712158B8
Authority
BR
Brazil
Prior art keywords
smallpox
producing
wild
attenuated
composition
Prior art date
Application number
BRPI0712158A
Other languages
English (en)
Inventor
Sene Claude
Malarme Daniel
Cordier Yves
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0712158(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of BRPI0712158A2 publication Critical patent/BRPI0712158A2/pt
Publication of BRPI0712158B1 publication Critical patent/BRPI0712158B1/pt
Publication of BRPI0712158B8 publication Critical patent/BRPI0712158B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Abstract

vírus de vacínia ankara modificado recombinante, processo para produzir um vírus da varíola de tipo selvagem, um vírus da varíola atenuado e/ou um vírus da varíola recombinante sem especificidade de infecção visada, composição, e, uso de um vírus da varíola recombinante ou de uma composição. a presente invenção refere-se às composições e as composições farmacêuticas compreendendo vírus da varíola e mais particularmente aos vírus envelopados extracelulares. a presente invenção também se refere a um processo para produzir vírus da varíola e aos vírus da varíola obtidos do mesmo. ainda mais, a presente invenção também se refere ao uso de citados vírus da varíola e citada composição para preparação de um medicamento.
BRPI0712158A 2006-06-20 2007-06-15 processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada BRPI0712158B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06360027 2006-06-20
EP06360027.4 2006-06-20
US86145206P 2006-11-29 2006-11-29
US60/816452 2006-11-29
PCT/EP2007/005302 WO2007147528A1 (en) 2006-06-20 2007-06-15 Process for producing poxviruses and poxvirus compositions

Publications (3)

Publication Number Publication Date
BRPI0712158A2 BRPI0712158A2 (pt) 2012-01-17
BRPI0712158B1 BRPI0712158B1 (pt) 2019-12-10
BRPI0712158B8 true BRPI0712158B8 (pt) 2021-05-25

Family

ID=40770647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712158A BRPI0712158B8 (pt) 2006-06-20 2007-06-15 processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada

Country Status (22)

Country Link
US (5) US8058049B2 (pt)
EP (2) EP2530161B1 (pt)
JP (1) JP5456464B2 (pt)
KR (1) KR101082296B1 (pt)
CN (1) CN101460627B (pt)
AU (1) AU2007263280B2 (pt)
BR (1) BRPI0712158B8 (pt)
CA (1) CA2656259C (pt)
CO (1) CO6141479A2 (pt)
CR (1) CR10528A (pt)
DK (2) DK2029756T3 (pt)
ES (2) ES2671230T3 (pt)
HK (1) HK1125405A1 (pt)
HU (2) HUE030533T2 (pt)
IL (1) IL194978A (pt)
MA (1) MA30580B1 (pt)
MX (2) MX348525B (pt)
NO (1) NO20084855L (pt)
NZ (1) NZ573437A (pt)
RU (3) RU2489486C2 (pt)
WO (1) WO2007147528A1 (pt)
ZA (1) ZA200810658B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
WO2009132195A1 (en) * 2008-04-23 2009-10-29 Michigan State University Immortal avian cell line and methods of use
AU2010205717A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
JP2012525830A (ja) * 2009-05-08 2012-10-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 均質化を含む細胞培養からのウイルスの製造方法
CA2760465A1 (en) * 2009-05-12 2010-11-18 Transgene Sa Method for orthopoxvirus production and purification
EP2456461A1 (en) 2009-07-21 2012-05-30 Transgene SA Enzymatic composition for the digestion of chicken embryos
CN102313803A (zh) * 2011-06-21 2012-01-11 贵州大学 山羊痘正向间接血凝诊断试剂及其制备方法和检测方法
KR101370620B1 (ko) * 2011-08-05 2014-03-06 한국생명공학연구원 다람쥐폭스바이러스를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
CN104147145B (zh) * 2014-07-31 2017-01-11 许峰 一种预防和治疗羊痘的药剂
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3641803A2 (en) * 2017-06-21 2020-04-29 Transgene Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
BR112020014727A2 (pt) * 2018-01-19 2020-12-08 Kolon Life Science, Inc. Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
WO2023128672A1 (ko) * 2021-12-29 2023-07-06 재단법인 아산사회복지재단 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023238106A1 (en) 2022-06-10 2023-12-14 Transgene Recombinant virus expressing interleukin-12
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
GB9208402D0 (en) 1992-04-16 1992-06-03 Devro Ltd Rotatable linking and hanging device
JPH08511423A (ja) 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US7348014B2 (en) 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
KR101044538B1 (ko) * 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
KR101062140B1 (ko) 2003-07-21 2011-09-05 트랜스진 에스.에이. 향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드
PL1646715T3 (pl) 2003-07-22 2010-10-29 Valneva Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS

Also Published As

Publication number Publication date
NZ573437A (en) 2012-02-24
ES2611975T3 (es) 2017-05-11
EP2530161B1 (en) 2018-03-28
MA30580B1 (fr) 2009-07-01
CN101460627B (zh) 2012-09-05
RU2551982C2 (ru) 2015-06-10
US8415134B1 (en) 2013-04-09
EP2029756B1 (en) 2016-11-09
ZA200810658B (en) 2009-12-30
WO2007147528A1 (en) 2007-12-27
BRPI0712158A2 (pt) 2012-01-17
RU2013119415A (ru) 2014-11-10
KR101082296B1 (ko) 2011-11-09
CA2656259C (en) 2013-03-19
US20150110746A1 (en) 2015-04-23
MX348525B (es) 2017-06-16
DK2530161T3 (en) 2018-06-06
BRPI0712158B1 (pt) 2019-12-10
CO6141479A2 (es) 2010-03-19
KR20090026295A (ko) 2009-03-12
HK1125405A1 (zh) 2009-08-07
HUE030533T2 (hu) 2017-05-29
JP2009540806A (ja) 2009-11-26
CA2656259A1 (en) 2007-12-27
EP2530161A2 (en) 2012-12-05
IL194978A (en) 2016-04-21
US20100008953A1 (en) 2010-01-14
CR10528A (es) 2009-05-14
AU2007263280B2 (en) 2012-09-13
EP2029756A1 (en) 2009-03-04
MX2008015166A (es) 2009-02-25
US20120276614A1 (en) 2012-11-01
DK2029756T3 (en) 2017-02-13
NO20084855L (no) 2009-01-20
JP5456464B2 (ja) 2014-03-26
RU2581910C2 (ru) 2016-04-20
RU2013119416A (ru) 2014-11-10
RU2489486C2 (ru) 2013-08-10
US20130084620A1 (en) 2013-04-04
US8945581B2 (en) 2015-02-03
US9295702B2 (en) 2016-03-29
AU2007263280A1 (en) 2007-12-27
US8058049B2 (en) 2011-11-15
IL194978A0 (en) 2011-08-01
RU2009101382A (ru) 2010-07-27
US20120093780A1 (en) 2012-04-19
ES2671230T3 (es) 2018-06-05
CN101460627A (zh) 2009-06-17
EP2530161A3 (en) 2013-11-06
HUE037866T2 (hu) 2018-09-28
US8415133B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
BRPI0712158B8 (pt) processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada
BR112022023106A2 (pt) Redirecionamento de tropismo de capsídeos de aav
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
BR112015024073A2 (pt) Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas
EA201270063A1 (ru) Рекомбинантные антигены pcb
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BR112015017069A2 (pt) processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
EA201491676A1 (ru) Партии рекомбинантного аденовируса с измененными концевыми областями
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
WO2009080806A3 (en) Modified influenza virus
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
MX2011012312A (es) Vacuna universal para influenza basada en virus vaccinia ankara (mva) modificado recombinante.
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201390812A1 (ru) Лиофилизированные вирусные составы
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
EA201491969A1 (ru) Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197
BR112015009453A2 (pt) composição farmacêutica estável de peg-interferona alfa-2b
BR112015006798A2 (pt) vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Ipc: A61K 35/76 (2015.01), A61K 39/00 (2006.01), A61K 3

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF